GlobalData on MSN5d
“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirlNovo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.
The needle device market is forecast to grow to over $6.8bn by 2033, according to analysis by GlobalData. Novo Nordisk’s investor relations manager David Heiberg Landsted confirmed the current ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback